| Expression pattern: |
UP |
| Associated gene: |
CCL20, CCR6, Akt, PI3K-Akt signaling pathway, CD68, CD163, CD206 |
| Associated microRNA: |
miR-1322 |
| Biological function: |
promotes PCa cell proliferation, migration, invasion and metastasis; promotes TAM infiltration and M2 polarization |
| Molecular mechanism: |
ceRNA (sponges miR-1322) to up-regulate CCL20, activating PI3K-Akt signaling and CCL20/CCR6-mediated crosstalk with TAMs |
| Biological pathway or process: |
PI3K/AKT (promotes); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); EMT (promotes); immune regulation (promotes); macrophage polarization (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
H
S
M
|
| Validation methods: |
RNA-seq; Microarray; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RNase R Treatment; Actinomycin D / DRB Stability Assay; divergent primers PCR; Sanger Sequencing; Luciferase Reporter Assay; RNA Pull-Down; Transfection; Western Blot; IHC (Immunohistochemistry); IF (Immunofluorescence); ELISA; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Cell Cycle Assay; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; H&E Staining; Clinical Sample Validation; ROC Analysis; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
circSMARCC1 is elevated in PCa plasma and tissues; ROC AUC=0.713 for PCa screening; high circSMARCC1 expression indicates a poorer prognosis (biochemical recurrence trend) and correlates with Gleason score and T-stage |
| Description: |
circSMARCC1 is up-regulated in prostate cancer and promotes proliferation, migration/invasion, and in vivo tumor growth/metastasis. It functions mainly in the cytoplasm as a ceRNA that sponges miR-1322 to de-repress CCL20, activates PI3K/AKT signaling, and enhances TAM recruitment and M2 polarization via the CCL20/CCR6 axis, contributing to PCa progression and poorer clinical outcomes. |
| Confidence score: |
0.8898 |